主营介绍

运营业务数据

最新公告日期:2017-04-18 
业务名称 2016-12-31 2015-12-31
7-ACA产量(吨) 2344.00 -
7-ACA销量(吨) 2314.00 -
注射用美罗培南销量(支) 1031.00万 -
注射用美罗培南产量(支) 992.00万 -
7-ACA产量(公斤) - 208.69万
7-ACA销量(公斤) - 200.05万

主营构成分析

{"2017-06-30":{"YYSR":{"1":[["\u5de5\u5546\u4e1a","539938.93"],["\u670d\u52a1\u4e1a","956.44"]],"2":[["\u5316\u5b66\u5236\u5242","241580.03"],["\u5316\u5b66\u539f\u6599\u836f\u53ca\u4e2d\u95f4\u4f53","150506.15"],["\u4e2d\u836f","109015.31"],["\u8bca\u65ad\u8bd5\u5242\u53ca\u8bbe\u5907","28886.63"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",10907.26]],"3":[["\u5883\u5185","470891.57"],["\u5883\u5916","70003.80"]]},"YYCB":{"1":[["\u5de5\u5546\u4e1a","196309.89"],["\u670d\u52a1\u4e1a","450.07"]],"2":[["\u5316\u5b66\u5236\u5242","44447.04"],["\u5316\u5b66\u539f\u6599\u836f\u53ca\u4e2d\u95f4\u4f53","112832.26"],["\u4e2d\u836f","22749.96"],["\u8bca\u65ad\u8bd5\u5242\u53ca\u8bbe\u5907","12586.54"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",4144.17]],"3":[["\u5883\u5185","142562.97"],["\u5883\u5916","54196.99"]]},"LRBL":{"1":[["\u5de5\u5546\u4e1a","99.85"],["\u670d\u52a1\u4e1a","0.15"]],"2":[["\u5316\u5b66\u5236\u5242","57.28"],["\u5316\u5b66\u539f\u6599\u836f\u53ca\u4e2d\u95f4\u4f53","10.95"],["\u4e2d\u836f","25.07"],["\u8bca\u65ad\u8bd5\u5242\u53ca\u8bbe\u5907","4.74"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",1.96]],"3":[["\u5883\u5185","95.41"],["\u5883\u5916","4.59"]]}},"2016-12-31":{"YYSR":{"1":[["\u5de5\u5546\u4e1a","963678.37"],["\u670d\u52a1\u4e1a","502.23"]],"2":[["\u5316\u5b66\u5236\u5242","409554.67"],["\u5316\u5b66\u539f\u6599\u836f\u53ca\u4e2d\u95f4\u4f53","261941.69"],["\u4e2d\u836f","213420.97"],["\u8bca\u65ad\u8bd5\u5242\u53ca\u8bbe\u5907","56857.49"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",22405.78]],"3":[["\u5883\u5185","838295.82"],["\u5883\u5916","125884.78"]]},"YYCB":{"1":[["\u5de5\u5546\u4e1a","360347.91"],["\u670d\u52a1\u4e1a","100.85"]],"2":[["\u5316\u5b66\u5236\u5242","74238.91"],["\u5316\u5b66\u539f\u6599\u836f\u53ca\u4e2d\u95f4\u4f53","210393.65"],["\u4e2d\u836f","43286.43"],["\u8bca\u65ad\u8bd5\u5242\u53ca\u8bbe\u5907","24863.79"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",7665.9800000000005]],"3":[["\u5883\u5185","253344.03"],["\u5883\u5916","107104.74"]]},"LRBL":{"1":[["\u5de5\u5546\u4e1a","99.93"],["\u670d\u52a1\u4e1a","0.07"]],"2":[["\u5316\u5b66\u5236\u5242","55.54"],["\u5316\u5b66\u539f\u6599\u836f\u53ca\u4e2d\u95f4\u4f53","8.54"],["\u4e2d\u836f","28.18"],["\u8bca\u65ad\u8bd5\u5242\u53ca\u8bbe\u5907","5.30"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",2.4499999999999997]],"3":[["\u5883\u5185","96.89"],["\u5883\u5916","3.11"]]}},"2016-06-30":{"YYSR":{"1":[["\u5de5\u5546\u4e1a","484991.12"],["\u670d\u52a1\u4e1a","1918.38"]],"2":[["\u5236\u5242\u4ea7\u54c1","316573.52"],["\u539f\u6599\u836f","129406.83"],["\u8bca\u65ad\u8bd5\u5242\u53ca\u8bbe\u5907","26043.66"],["\u4fdd\u5065\u54c1","14495.16"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",390.33]],"3":[["\u73e0\u6d77\u5e02","381464.16"],["\u6df1\u5733\u5e02","116672.77"],["\u6cb3\u5357\u7701","50516.44"],["\u4e0a\u6d77\u5e02","745.00"],["\u5185\u90e8\u62b5\u9500","-62488.87"]]},"YYCB":{"1":[["\u5de5\u5546\u4e1a","179994.39"],["\u670d\u52a1\u4e1a","1067.28"]],"2":[["\u5236\u5242\u4ea7\u54c1","61002.63"],["\u539f\u6599\u836f","103923.53"],["\u8bca\u65ad\u8bd5\u5242\u53ca\u8bbe\u5907","11109.63"],["\u4fdd\u5065\u54c1","4610.84"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",415.05]],"3":[["\u73e0\u6d77\u5e02","135642.93"],["\u6df1\u5733\u5e02","62560.48"],["\u6cb3\u5357\u7701","43168.85"],["\u4e0a\u6d77\u5e02","190.06"],["\u5185\u90e8\u62b5\u9500","-60500.63"]]},"LRBL":{"1":[["\u5de5\u5546\u4e1a","99.72"],["\u670d\u52a1\u4e1a","0.28"]],"2":[["\u5236\u5242\u4ea7\u54c1","83.56"],["\u539f\u6599\u836f","8.33"],["\u8bca\u65ad\u8bd5\u5242\u53ca\u8bbe\u5907","4.88"],["\u4fdd\u5065\u54c1","3.23"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",-0.0081]],"3":[["\u73e0\u6d77\u5e02","80.37"],["\u6df1\u5733\u5e02","17.69"],["\u6cb3\u5357\u7701","2.40"],["\u4e0a\u6d77\u5e02","0.18"],["\u5185\u90e8\u62b5\u9500","-0.65"]]}}}
{"YYSR":{"chartWrap1":[{"name":"\u5de5\u5546\u4e1a","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[539938.93,963678.37,484991.12],"columnData":[99.82,99.95,99.61],"unit":["53.99\u4ebf","96.37\u4ebf","48.50\u4ebf"]},{"name":"\u670d\u52a1\u4e1a","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[956.44,502.23,1918.38],"columnData":[0.18,0.05,0.39],"unit":["956.44\u4e07","502.23\u4e07","1918.38\u4e07"]}],"chartWrap2":[{"name":"\u5316\u5b66\u5236\u5242","timeData":["2017-06-30","2016-12-31"],"lineData":[241580.03,409554.67],"columnData":[44.66,42.48],"unit":["24.16\u4ebf","40.96\u4ebf"]},{"name":"\u5316\u5b66\u539f\u6599\u836f\u53ca\u4e2d\u95f4\u4f53","timeData":["2017-06-30","2016-12-31"],"lineData":[150506.15,261941.69],"columnData":[27.83,27.17],"unit":["15.05\u4ebf","26.19\u4ebf"]},{"name":"\u4e2d\u836f","timeData":["2017-06-30","2016-12-31"],"lineData":[109015.31,213420.97],"columnData":[20.15,22.13],"unit":["10.90\u4ebf","21.34\u4ebf"]},{"name":"\u8bca\u65ad\u8bd5\u5242\u53ca\u8bbe\u5907","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[28886.63,56857.49,26043.66],"columnData":[5.34,5.9,5.35],"unit":["2.89\u4ebf","5.69\u4ebf","2.60\u4ebf"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[10907.26,22405.78,390.33],"columnData":[2.02,2.3199999999999994,0.08],"unit":["1.09\u4ebf","2.24\u4ebf","390.33\u4e07"]},{"name":"\u5236\u5242\u4ea7\u54c1","timeData":["2016-06-30"],"lineData":[316573.52],"columnData":[65.02],"unit":["31.66\u4ebf"]},{"name":"\u539f\u6599\u836f","timeData":["2016-06-30"],"lineData":[129406.83],"columnData":[26.58],"unit":["12.94\u4ebf"]},{"name":"\u4fdd\u5065\u54c1","timeData":["2016-06-30"],"lineData":[14495.16],"columnData":[2.98],"unit":["1.45\u4ebf"]}],"chartWrap3":[{"name":"\u5883\u5185","timeData":["2017-06-30","2016-12-31"],"lineData":[470891.57,838295.82],"columnData":[87.06,86.94],"unit":["47.09\u4ebf","83.83\u4ebf"]},{"name":"\u5883\u5916","timeData":["2017-06-30","2016-12-31"],"lineData":[70003.8,125884.78],"columnData":[12.94,13.06],"unit":["7.00\u4ebf","12.59\u4ebf"]},{"name":"\u73e0\u6d77\u5e02","timeData":["2016-06-30"],"lineData":[381464.16],"columnData":[78.34],"unit":["38.15\u4ebf"]},{"name":"\u6df1\u5733\u5e02","timeData":["2016-06-30"],"lineData":[116672.77],"columnData":[23.96],"unit":["11.67\u4ebf"]},{"name":"\u6cb3\u5357\u7701","timeData":["2016-06-30"],"lineData":[50516.44],"columnData":[10.37],"unit":["5.05\u4ebf"]},{"name":"\u4e0a\u6d77\u5e02","timeData":["2016-06-30"],"lineData":[745],"columnData":[0.15],"unit":["745.00\u4e07"]},{"name":"\u5185\u90e8\u62b5\u9500","timeData":["2016-06-30"],"lineData":[-62488.87],"columnData":[-12.83],"unit":["-6.25\u4ebf"]}]},"YYCB":{"chartWrap1":[{"name":"\u5de5\u5546\u4e1a","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[196309.89,360347.91,179994.39],"columnData":[99.77,99.97,99.41],"unit":["19.63\u4ebf","36.03\u4ebf","18.00\u4ebf"]},{"name":"\u670d\u52a1\u4e1a","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[450.07,100.85,1067.28],"columnData":[0.23,0.03,0.59],"unit":["450.07\u4e07","100.85\u4e07","1067.28\u4e07"]}],"chartWrap2":[{"name":"\u5316\u5b66\u5236\u5242","timeData":["2017-06-30","2016-12-31"],"lineData":[44447.04,74238.91],"columnData":[22.59,20.6],"unit":["4.44\u4ebf","7.42\u4ebf"]},{"name":"\u5316\u5b66\u539f\u6599\u836f\u53ca\u4e2d\u95f4\u4f53","timeData":["2017-06-30","2016-12-31"],"lineData":[112832.26,210393.65],"columnData":[57.35,58.37],"unit":["11.28\u4ebf","21.04\u4ebf"]},{"name":"\u4e2d\u836f","timeData":["2017-06-30","2016-12-31"],"lineData":[22749.96,43286.43],"columnData":[11.56,12.01],"unit":["2.27\u4ebf","4.33\u4ebf"]},{"name":"\u8bca\u65ad\u8bd5\u5242\u53ca\u8bbe\u5907","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[12586.54,24863.79,11109.63],"columnData":[6.4,6.9,6.14],"unit":["1.26\u4ebf","2.49\u4ebf","1.11\u4ebf"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[4144.17,7665.9800000000005,415.05],"columnData":[2.0999999999999996,2.13,0.23],"unit":["4144.17\u4e07","7665.98\u4e07","415.05\u4e07"]},{"name":"\u5236\u5242\u4ea7\u54c1","timeData":["2016-06-30"],"lineData":[61002.63],"columnData":[33.69],"unit":["6.10\u4ebf"]},{"name":"\u539f\u6599\u836f","timeData":["2016-06-30"],"lineData":[103923.53],"columnData":[57.4],"unit":["10.39\u4ebf"]},{"name":"\u4fdd\u5065\u54c1","timeData":["2016-06-30"],"lineData":[4610.84],"columnData":[2.55],"unit":["4610.84\u4e07"]}],"chartWrap3":[{"name":"\u5883\u5185","timeData":["2017-06-30","2016-12-31"],"lineData":[142562.97,253344.03],"columnData":[72.46,70.29],"unit":["14.26\u4ebf","25.33\u4ebf"]},{"name":"\u5883\u5916","timeData":["2017-06-30","2016-12-31"],"lineData":[54196.99,107104.74],"columnData":[27.54,29.71],"unit":["5.42\u4ebf","10.71\u4ebf"]},{"name":"\u73e0\u6d77\u5e02","timeData":["2016-06-30"],"lineData":[135642.93],"columnData":[74.92],"unit":["13.56\u4ebf"]},{"name":"\u6df1\u5733\u5e02","timeData":["2016-06-30"],"lineData":[62560.48],"columnData":[34.55],"unit":["6.26\u4ebf"]},{"name":"\u6cb3\u5357\u7701","timeData":["2016-06-30"],"lineData":[43168.85],"columnData":[23.84],"unit":["4.32\u4ebf"]},{"name":"\u4e0a\u6d77\u5e02","timeData":["2016-06-30"],"lineData":[190.06],"columnData":[0.1],"unit":["190.06\u4e07"]},{"name":"\u5185\u90e8\u62b5\u9500","timeData":["2016-06-30"],"lineData":[-60500.63],"columnData":[-33.41],"unit":["-6.05\u4ebf"]}]},"LRBL":{"chartWrap1":[{"name":"\u5de5\u5546\u4e1a","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[99.85,99.93,99.72],"columnData":[99.85,99.93,99.72],"unit":["99.85\u4e07","99.93\u4e07","99.72\u4e07"]},{"name":"\u670d\u52a1\u4e1a","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[0.15,0.07,0.28],"columnData":[0.15,0.07,0.28],"unit":["1500.00","700.00","2800.00"]}],"chartWrap2":[{"name":"\u5316\u5b66\u5236\u5242","timeData":["2017-06-30","2016-12-31"],"lineData":[57.28,55.54],"columnData":[57.28,55.54],"unit":["57.28\u4e07","55.54\u4e07"]},{"name":"\u5316\u5b66\u539f\u6599\u836f\u53ca\u4e2d\u95f4\u4f53","timeData":["2017-06-30","2016-12-31"],"lineData":[10.95,8.54],"columnData":[10.95,8.54],"unit":["10.95\u4e07","8.54\u4e07"]},{"name":"\u4e2d\u836f","timeData":["2017-06-30","2016-12-31"],"lineData":[25.07,28.18],"columnData":[25.07,28.18],"unit":["25.07\u4e07","28.18\u4e07"]},{"name":"\u8bca\u65ad\u8bd5\u5242\u53ca\u8bbe\u5907","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[4.74,5.3,4.88],"columnData":[4.74,5.3,4.88],"unit":["4.74\u4e07","5.30\u4e07","4.88\u4e07"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2017-06-30","2016-12-31","2016-06-30"],"lineData":[1.96,2.4499999999999997,-0.0081],"columnData":[1.96,2.4499999999999997,-0.0081],"unit":["1.96\u4e07","2.45\u4e07","-81"]},{"name":"\u5236\u5242\u4ea7\u54c1","timeData":["2016-06-30"],"lineData":[83.56],"columnData":[83.56],"unit":["83.56\u4e07"]},{"name":"\u539f\u6599\u836f","timeData":["2016-06-30"],"lineData":[8.33],"columnData":[8.33],"unit":["8.33\u4e07"]},{"name":"\u4fdd\u5065\u54c1","timeData":["2016-06-30"],"lineData":[3.23],"columnData":[3.23],"unit":["3.23\u4e07"]}],"chartWrap3":[{"name":"\u5883\u5185","timeData":["2017-06-30","2016-12-31"],"lineData":[95.41,96.89],"columnData":[95.41,96.89],"unit":["95.41\u4e07","96.89\u4e07"]},{"name":"\u5883\u5916","timeData":["2017-06-30","2016-12-31"],"lineData":[4.59,3.11],"columnData":[4.59,3.11],"unit":["4.59\u4e07","3.11\u4e07"]},{"name":"\u73e0\u6d77\u5e02","timeData":["2016-06-30"],"lineData":[80.37],"columnData":[80.37],"unit":["80.37\u4e07"]},{"name":"\u6df1\u5733\u5e02","timeData":["2016-06-30"],"lineData":[17.69],"columnData":[17.69],"unit":["17.69\u4e07"]},{"name":"\u6cb3\u5357\u7701","timeData":["2016-06-30"],"lineData":[2.4],"columnData":[2.4],"unit":["2.40\u4e07"]},{"name":"\u4e0a\u6d77\u5e02","timeData":["2016-06-30"],"lineData":[0.18],"columnData":[0.18],"unit":["1800.00"]},{"name":"\u5185\u90e8\u62b5\u9500","timeData":["2016-06-30"],"lineData":[-0.65],"columnData":[-0.65],"unit":["-6500"]}]}}

营业收入 X

单位(%) 单位(万元)
注:通常在中报、年报时披露 
业务名称 营业收入(元) 收入比例 营业成本(元) 成本比例 利润比例 毛利率
按行业 工商业 53.99亿 99.82% 19.63亿 99.77% 99.85% 63.64%
服务业 956.44万 0.18% 450.07万 0.23% 0.15% 52.94%
按产品 化学制剂 24.16亿 44.66% 4.44亿 22.59% 57.28% 81.60%
化学原料药及中间体 15.05亿 27.83% 11.28亿 57.35% 10.95% 25.03%
中药 10.90亿 20.15% 2.27亿 11.56% 25.07% 79.13%
诊断试剂及设备 2.89亿 5.34% 1.26亿 6.40% 4.74% 56.43%
保健品 1.07亿 1.97% 4076.45万 2.07% 1.91% 61.76%
其他 246.54万 0.05% 67.72万 0.03% 0.05% 72.53%
按地区 境内 47.09亿 87.06% 14.26亿 72.46% 95.41% 69.72%
境外 7.00亿 12.94% 5.42亿 27.54% 4.59% 22.58%

董事会经营评述

  一、经营情况的讨论与分析。
  1、报告期内主要经营情况。
  报告期内,本公司实现营业收入54.43亿元,较上年同期上升5.32亿元,升幅约为10.84%,主要系本公司子公司海滨制药、焦作健康元及丽珠集团销售收入增加所致;报告期内,本公司实现归属于上市公司股东的净利润3.27亿元,较上年同期上升约0.70亿元,升幅约为27.07%,主要系公司总体销售收入增加所致。报告期内,本公司实现归属于上市公司股东扣除非经常性损益的净利润为2.90亿元,较上年同期上升0.63亿元,升幅约为27.99%。
  报告期内,公司保健品及OTC业务(不含丽珠集团OTC)实现销售收入1.58亿元,较上年同期下降... 查看全部▼

  一、经营情况的讨论与分析。
  1、报告期内主要经营情况。
  报告期内,本公司实现营业收入54.43亿元,较上年同期上升5.32亿元,升幅约为10.84%,主要系本公司子公司海滨制药、焦作健康元及丽珠集团销售收入增加所致;报告期内,本公司实现归属于上市公司股东的净利润3.27亿元,较上年同期上升约0.70亿元,升幅约为27.07%,主要系公司总体销售收入增加所致。报告期内,本公司实现归属于上市公司股东扣除非经常性损益的净利润为2.90亿元,较上年同期上升0.63亿元,升幅约为27.99%。
  报告期内,公司保健品及OTC业务(不含丽珠集团OTC)实现销售收入1.58亿元,较上年同期下降18.72%;实现净利润贡献为0.27亿元,较上年同期下降约34.22%,主要系营销模式调整和推广活动效率降低导致。随着近年来媒体投放的性价比持续下降,公司保健品已经逐步将原来的“广告+渠道”模式调整为“渠道+地面推广”模式,并积极探索新模式。随着竞争加剧,地面推广活动的效率大幅度降低。此外,2015年开始大力布局的微商渠道因行业环境变化而销量大幅度下降,而新模式尚未走出探索阶段。
  下半年,公司将继续加大电商、社交电商等新渠道开放及推进力度,加快探索新模式,深化同现有药线渠道的战略合作,锁定现有渠道垂直健康人群,共同提升用户健康服务体验,增强客户粘性、提升品牌渗透率和忠诚度,为满足消费升级和符合消费趋势,针对性的开发和推进新品上市。
  报告期内,公司海滨制药产品实现营业收入6.92亿元,较上年同期上升约0.58亿元,升幅为9.18%;实现净利润贡献为1.24亿元,较上年同期上升0.06亿元,升幅为4.71%,主要系因美罗培南制剂(倍能)销售数量提升带来营业收入的稳步提升。报告期内,海滨制药继续优化处方药销售模式,优化资源充分配置及细化考核管理,实现处方药销售的稳定增长,其中重点产品倍能销售数量较上年同期增长约19.68%,销售收入同比增长16.31%。
  报告期内,焦作健康元实现销售收入4.87亿元,实现净利润贡献为0.29亿元,较上年同期分别增长10.59%和17.66%,主要系因7-ACA产品销售数量增加带来营业收入和净利润的提升。
  今年上半年7-ACA的平均销售价格较上年同期略有下降,仍处于历史低位。为了应对目前原料药市场的困境,焦作健康元在原有成本下降基础上,积极研发新配方、新工艺,动力、环保车间等加大排查力度,充分贯彻并执行节能减排,同时加强销售市场维护,稳定市场占有率,积极开拓新客户,为公司的持续盈利创造条件。公司也将积极引进及开发新产品,发展以发酵原料药中间体为主,向上和向下延伸产业链,增强市场抗风险能力,做到头孢品种的多元化,另外争取通过相关国际认证,打开高端市场,提高品种毛利及市场竞争力,保证公司利润。
  报告期内,本公司控股子公司丽珠集团(000513.SZ,01513.HK)实现营业收入42.75亿元,较上年同期上升4.91亿元;实现其归属于上市公司股东的净利润5.04亿元,为本公司贡献归属于母公司股东的净利润约2.29亿元;丽珠集团实现扣除非经常性损益后的净利润为4.55亿元,为本公司扣除非经常性损益后的净利润贡献约2.07亿元。丽珠集团经营情况详见《丽珠集团2017年半年度报告》。
  2、下半年工作重点。
  2017年下半年,公司将积极应对行业变革及市场竞争所带来的各种机遇和挑战,加大对研发、生产、质量、销售等多个环节的管理力度,保证公司业绩的稳步发展,努力实现股权激励考核目标。
  本公司2017年下半年主要工作重点如下:
  (一)提升销售业绩。
  在制剂产品方面,全面启动二级以下医疗机构的营销,加强二级以下管理团队的团队建设及考核机制,除巩固已有医院市场外,公司将积极开拓部分产品的OTC市场,多渠道增加销售量,并进一步提升品牌影响力。
  在原料药及中间品方面,坚持以“保环保、抓质量、降成本”为工作指导方针,巩固提升生产技术水平,推进重点产品成本攻关计划;引进和研发高毛利、低能耗、低排放的产品;持续开展原料药国际认证,进一步扩展国际市场。
  在保健品方面,加大电商、社交电商等新渠道开放及推进力度,加快探索新模式。同时深化同现有药线渠道的战略合作,锁定现有渠道垂直健康人群,共同提升用户健康服务体验,增强客户粘性、提升品牌渗透率和忠诚度,以提升业绩。
  (二)推进研发创新工作。
  公司将继续加大研发投入,加快抗体技术平台、微球缓释技术平台等特色创新技术平台的建设,加快呼吸系统、糖尿病、新型抗感染药物、单抗、传统中药及保健品等重点产品的研发进度,加快成果转化,进一步完善公司产品结构和业务布局,提升核心竞争力。
  (三)提高公司治理水平。
  公司将进一步加强公司内控机制建设及改进工作,梳理及制定各项管理规章制度,继续强化内部治理,防范经营风险,完善法人治理结构。同时,通过信息披露与交流,加强与投资者及潜在投资者之间的沟通,以增进投资者对公司的了解和认同,提升公司治理水平。

  二、报告期内公司所从事的主要业务、经营模式及行业情况说明。
  (一)本公司主要业务及产品。
  本公司主要从事医药产品及保健品研发、生产及销售,根据中国证监会颁发的《上市公司行业分类指引》(2012年修订),公司所处行业为医药制造业(C27)。
  目前,公司业务范围涵盖保健品、化学制剂、中药、化学原料药及中间体、诊断试剂及设备等多重领域。保健品业务已从公司成立之初延续至今,“太太”、“静心”、“鹰牌”等知名品牌具有广泛的市场影响力;化学制剂为公司第一大收入来源,其中的处方药包含消化道用药、心脑血管用药、抗微生物用药、抗肿瘤药、神经系统用药、泌尿系统用药等多个领域,非处方药包含消化道用药“丽珠得乐”、“丽珠肠乐”及口腔溃疡用药“意可贴”等;化学原料药及中间体包括抗生素系列及其中间体7-ACA(酶法)等;中药包含抗肿瘤扶正用药“参芪扶正注射液”和感冒类药品“抗病毒口服颗粒”等。
  (二)本公司经营模式。
  1、采购模式。
  公司在采购方面严格注重采购效率、采购质量及采购成本,已与多个供应商建立了长期稳定合作关系。原料、辅料、包装材料由各生产企业根据生产进度进行采购备货。公司制定有严格的质量标准和采购管理制度,并严格要求下属各生产企业按GMP标准组织采购,同时与大宗物资供货商建立长期战略合作关系,并在严控质量标准的基础上,加强对供应质量以及成本控制的管理。公司内部建立有评价体系与价格档案,便于及时掌握市场信息,实行比质、比价采购。
  2、生产模式。
  公司生产方面采取以市场需求为导向组织生产的原则,具体方式为:由公司销售部门对市场需求情况进行调查并制订销售计划,综合考虑公司各产品库存数量和各产品生产线的产能情况等因素,决定公司当月各产品的生产数量和产品规格;同时,根据生产计划和原材料的库存量决定原材料的采购。最终生产计划经公司经营管理层审核后下达,并由公司生产技术部门具体负责组织实施。
  公司严格按照GMP的要求组织生产,公司和各下属企业均已建立完善的质量管理体系,并实施质量授权人制度。在质量管控方面,公司已建立严密、完善的生产质量保证(QA)体系,在符合国家标准的基础上,与国际接轨并接受国际认证。公司每年进行GMP自检、ISO9001内审外审,以及接受各种外部审计,公司积极推行国际先进的GMP管理,对供应商筛选、审计、进厂物料检验、生产过程控制、产品出厂放行、市场跟踪等全过程进行质量控制,体系运行良好。
  3、销售模式。
  (1)原料药。
  原料药产品具体销售方式包括:
  1)国内市场:公司主要采取直接销售方式,即与大型生产企业直接签订产品销售合同,直接销售给客户。
  2)国外市场:公司国外市场采取直接销售方式,对于风险因素较高地区则兼以经销商方式并行,目前公司产品主要出口亚洲、欧洲、北美、非洲等近40个国家和地区。
  (2)药品(含试剂)。
  公司已建立覆盖国内市场的营销网络,并与商业主渠道和数万家医院、诊所、药店等终端客户建立了稳定、良好的业务关系,销售模式以自主销售为主,招商为辅。公司处方药均自行销售,OTC产品基本通过商业配送终端覆盖,主要和国药控股、上海医药(集团)有限公司、华润医药商业集团以及当地的医药商业龙头公司进行合作。
  (3)保健品。
  保健品的销售模式主要为经销商管理模式。通过经销商分销渠道以及终端覆盖的能力,对产品推广促销、价格管控、渠道梳理等进行管理与完善。除了传统的经销管理模式外,公司通过电子商务渠道协同营销,还开辟了微商、云商等新的销售模式和渠道,共同发展。
  (三)报告期业绩驱动因素。
  2017年上半年,面对不利的外部环境及严峻的市场挑战,公司依托多年形成的品牌优势和产品集群优势,通过不断深化营销体系改革和管理创新,保持了营业收入和净利润的稳步增长,报告期内,公司不断深化营销改革,全力推行渠道下沉,加快销售专科领域建设,化学制剂销售收入同比增长14.44%,特色专科领域重点品种销售收入增长显著,其中消化道领域重点品种艾普拉唑肠溶片销售收入约2.09亿元,同比增长46.77%;促性激素领域重点品种注射用醋酸亮丙瑞林销售收入约2.82亿元,同比增长45.77%。原料药及中间体领域通过资源整合、调整产品结构,加大国际认证等措施,也取得了良好的销售业绩,销售收入比上年同期增长16.30%。

  三、报告期内核心竞争力分析。
  1、品牌优势。
  公司成立二十多年来,一直专注于医药、保健品领域的经营,其优良的产品质量及市场服务等树立了公司长久以来成功的品牌形象,并为公司赢得了广泛的市场认可。公司保健品“太太”、“静心”、“鹰牌”,处方药“倍能”、“速能”及丽珠集团旗下系列产品的众多品牌,为公司赢得了广泛知名度和品牌优势。
  2、产品结构多元化,高端专项品种市场优势明显。
  公司产品涵盖保健品及OTC、原料药、中药制剂、化学药制剂、生物医药领域,具体产品覆盖保健食品、抗微生物用药、消化系统用药、心血管系统用药、神经类治疗用药、抗肿瘤用药、泌尿系统用药及促性激素用药、诊断试剂等,丰富的产品阵容及品类为公司现在及未来发展获取了更多市场机会及发展空间,其中某些单类产品,如7-ACA、美罗培南原料药及制剂、抗病毒颗粒及参芪扶正注射液等,市场占有率及行业优势明显,为公司带来丰厚利润回报的同时,更进一步有效提升公司市场形象。
  3、研发创新优势。
  公司拥有多元化、多层次的研发机构,在化学和中药制剂、生物药、诊断试剂、保健品及食品等领域均有较强的研发能力及国际化的研发理念,围绕抗微生物、抗肿瘤、促性激素、消化、神经及呼吸等领域的产品线布局,形成了较为清晰的产品研发管线。通过积极引进国内外资深专家和创新型人才,加大研发投入、海外战略联盟等方式,进一步增强了公司的研发竞争力。
  4、营销模式革新带来企业增值。
  我国健康产业未来趋势将会是新兴互联网营销与传统产业相结合模式,传统产业依托互联网,特别是移动互联网,提高销售转化率,增加客户及消费者粘性。为此,公司亦不断尝试及推动各种以互联网为依托的新型营销模式,传统销售模式与新型互联网营销的并举,使公司直接建立与最终消费者间长期良好的互动关系,有效增强对消费者的长期价值及增值服务。
  5、持续营销改革及创新提升终端竞争优势。
  持续的公司营销方式及队伍的改革及创新,使得公司的销售队伍更具自主性、竞争力及挑战性,加上通过常年的积极互动保持了和各级经销商良好的合作关系。
  公司采用简政放权增强合约销售商自主销售决策能力的新型营销模式,在调动公司营销人员工作热情及积极性的同时,更是实现了公司、人员、品种、终端、政策等资源优化配置,扩大了公司产品推广及覆盖,实现了公司营业收入的有效增长。
  6、人才优势。
  人才是公司发展的核心,多年来,公司高效的运行管理模式及薪资培训体系,已凝聚一批高新技术创新型人才和管理团队。公司整体人才队伍中不仅有高端药学科研人员,深谙药事法规、药品生产的专业人员,更有行业经验资深、管理经验强劲的高端管理型人才,为公司健康持续稳定发展保驾护航。 收起▲